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Summary 
Plasma levels of the CTAP-III antigen were measured by radioimmunoassay in 80 
patients with rheumatic diseases. Patients with clear evidence of vasculitis usually 
exhibited increased plasma CTAP-III antigen. In both systemic lupus erythematosus 
and rheumatoid arthritis, there appeared to be a correlation between pCTAP-III 
values and other laboratory and clinical parameters of disease activity. 
Introduction 
Information concerning growth factors, long restricted to the arena of experi- 
mentalists working with in vitro systems, has contributed to the understanding of 
human disease beginning with the discovery of the family of somatomedin molecules 
[l]. The current literature emphasizes the possible importance of growth factors in 
regulating connective tissue metabolism [2], and one recent review drew attention to 
a possible role of platelet-derived growth factors (PDGF) in atherosclerosis, onco- 
genesis and myelofibrosis [3]. 
Definition of the clinical relevance of platelet-specific proteins in human disease 
should be undertaken cautiously in view of evidence that there are two or more 
distinct platelet growth factors [4-71. Unlike the somatomedin group of mediators, 
the growth factors found in human platelets do not depend on the presence of 
circulating human growth hormone [8]. A role has been postulated for platelet 
growth factors in the pathogenesis of connective tissue diseases which exhibit a 
“growth” (proliferative) component, such as rheumatoid arthritis (RA), systemic 
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lupus erythematosus (SLE) and less common types of vasculitis. Platelet abnormali- 
ties have been demonstrated in RA, SLE and other vascular diseases, and disease 
activity in RA appeared to correlate with thrombocytosis [9- 111. The destructive, 
proliferative pannus and accelerated formation of glycosaminoglycans (GAG) char- 
acteristic of RA clearly invite a search for a disorder of “growth factors”. Because 
such factors stimulate many connective tissue cell functions in vitro, we termed them 
Connective Tissue Activating Peptides (CTAP’s) [5]. 
CTAP-III is a biologically active platelet-specific protein which has been purified 
to homogeneity and shown to be antigenically identical to beta-thromboglobulin 
(P-TG) [5,12,13]. Although CTAP-III and P-TG are antigenically identical, CTAP-III 
is larger by an N-terminal tetrapeptide, suggesting that the biologically inactive 
P-TG is a degradation product of CTAP-III [14]. Known biologic actions of 
CTAP-III include stimulation of prostaglandin E, (PGE,) formation, increased 
intracellular cyclic 3’,5’ adenosine monophosphate (CAMP) accumulation, increased 
hyaluronic acid synthetase activity, increased hyaluronic acid (HA) formation, 
increased non-HA GAG synthesis and increased DNA synthesis [ 15,161. 
CTAP-III is known to be released by thrombin-induced. platelet aggregation. The 
antigenically identical degradation product, P-TG, was found to be elevated in 
plasma from patients with deep vein thrombosis, peripheral vascular disease, 
myocardial infarction, cerebral thrombosis, thrombotic thrombocytopenic purpura, 
diabetes mellitus and preeclampsia [ 17-211. Recently, plasma CTAP-III antigen 
levels were shown to be elevated in most patients with rheumatoid arthritis [22]. In 
view of platelet abnormalities associated with the vascular disease of RA, SLE and 
other rheumatic disease, the present study of CTAP-III antigen was directed at these 
patient groups. 
Materials and methods 
A total of 80 patients was studied; 56 with rheumatoid arthritis, 15 with SLE, and 
9 patients with other rheumatic diseases. Patients with rheumatoid arthritis and SLE 
fulfilled ARA criteria for these diseases. Ten RA patients were examined monthly 
for 6 months with assessment of 50 foot walking time, grip strength, duration of 
morning stiffness, Westergren erythrocyte sedimentation rate (ESR), platelet count 
and plasma CTAP (pCTAP). Routine laboratory studies included a complete blood 
count, urinalysis and measurement of serum creatinine. Patients with chronic renal 
failure were excluded from the study. Only 1 SLE patient had a slightly elevated 
serum creatinine (1.7 mg W). “Joint counts” provided a semiquantitative clinical 
estimate of RA disease activity based on the number of joints involved. with 
tenderness (scored as 0 or 1) and swelling (scored as 0 or 1). Latex titer for 
rheumatoid factor was determined every 2 months. In selected patients, total 
hemolytic complement (CH,,) was measured by a standard method. DNA binding 
was measured by a Farr technique using double stranded 14C-DNA prepared from 
human cells. 
Venous blood samples were drawn in duplicate, one from each arm, using 20 
gauge needles and plastic syringes. 2.5 ml of blood were obtained and immediately 
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transferred to plastic tubes containing 0.3 ml of EDTA and theophylline to inhibit 
the platelet release reaction [22]. Blood samples were immediately placed on ice and 
centrifuged at 1500 X g for 30 min at 4°C. 0.5 ml was removed from the upper layer 
of plasma and frozen at -70°C. Since traumatic vena puncture may elevate 
pCTAP-III levels, blood from both arms was analyzed. In 128 pairs of measure- 
ments of CTAP-III antigen from both arms of subjects, values were concordant 
(similarly low or similarly high) in 116 instances (90%). If one arm-only yields a high 
value, trauma has usually been recorded. Trauma to the initial arm does not result in 
a high value in the opposite arm. With discordant circumstances, the high value is 
discarded. Ideally, the measurement should be repeated at a later time. pCTAP-III 
antigen levels were measured by radioimmunoassay as described recently [ 131. In 
brief, this RIA employes antisera raised in rabbits against homogeneous, biologically 
active CTAP-III isolated from human platelets, and ‘251-CTAP-III prepared by a 
chloramine T method. Operationally, the competition between “cold” sample CTAP 
-111 and ‘251-CTAP-III for anti-CTAP-III antibody is assessed by determining the 
radioactivity in an immune precipitate formed by addition of a “second” antibody 
(goat anti-rabbit IgG). 
Results 
Plasma CTAP-III levels in 20 normal control subjects had a mean value of 
29.4 k 5.8 ng/ml with a median level of 28 ng/ml [22]. Patients with rheumatoid 
arthritis, SLE and other rheumatic diseases all showed many significantly elevated 
plasma CTAP-III values (Fig. 1). The mean CTAP-III value for RA patients was 81 
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Fig. I. A large proportion of patients with active rheumatic disease have an elevated pCTAP-III 
12X 
ng/ml, ranging from 20-2050 ng/ml. The mean pCTAP-III level for the SLE 
patients was 129 ng/ml with a range of 20-320 ng/ml. 
Of the 10 RA patients followed serially for 6 months, 6 had pCTAP-III levels that 
correlated with clinical estimates of disease activity, and in general, with ESR and 
joint count. Two patients had pCTAP-III values which correlated with disease 
activity assessed subjectively, but not with ESR and joint count. In the other 2 RA 
patients, pCTAP-III levels showed no obvious correlation with disease activity. Data 
from a patient with active rheumatoid arthritis and a flare of pericarditis is shown in 
Fig. 2. A patient with mild, stable rheumatoid arthritis had persistentIy normal 
pCTAP-III levels (Fig. 3). 
Twelve of 15 patients with SLE had elevated pCTAP-III levels, and 9 of the 12 
had high DNA binding values (Fig. 4). Ten of 13 patients with abnormal pCTAP-III 
values had a low CH,,, and of the 13 patients, 10 had very active to moderate 
disease activity (Fig. 4). Of the 3 patients with normal pCTAP-III values, 1 had a 
normal CH,, and 2 had low CH,, values, Fig. 5 is of interest in that it demonstrates 
that the concordance between DNA binding and CH,, was of the same order as that 
between CTAP-III and DNA binding or CH,,. 
CTAP-III values in patients with miscellaneous rheumatic.diseases are shown in 
Table I. Two patients with early scleroderma had normal pCTAP-III levels, while 
another with digital ulcers had an elevated value. One of the 2 patients with 
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Fig. 2. Patient S.R. developed pericarditis believed to be an extraarticular manifestation of active 
rheumatoid arthritis: this was accompanied by increased articular and laboratory abnormalities. 
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Fig. 3. Patient E.G. had clinically mild, stable rheumatoid arthritis. 
Wegener’s granulomatosis had elevated pCTAP-III associated with severe disease 
and digital ulcers; the other had minimal disease activity and was in remission on 
prednisone and cyclophosphamide. One patient with polyarteritis nodosa had a very 
high platelet factor level concurrent with very active clinical disease. A patient with 
temporal arteritis and an ESR of 120 mm/h had a pCTAP-III of 175 ng/ml; values 
which returned to normal after 2 months of prednisone therapy. A patient with 
polymyalgia rheumatica had a normal pCTAP-III value in the face of moderate to 
severe disease activity. 
Six additional patients with rheumatoid arthritis, most with very active disease, a 
high ESR and high latex titers are reviewed in Table II. One patient with Felty’s 
syndrome, rheumatoid nodules and lower extremity ulcers had a pCTAP-III value of 
190 “g/ml. Two other patients with high latex titers had pCTAP-III values of 250 
ng/ml. One of these patients had mild disease, the other had moderate disease 
activity. A patient with low latex titer, Raynaud’s phenomenon, Sjogren’s syndrome 
and RA had a pCTAP-III value of 140 “g/ml. 
Discussion 
In the present study, pCTAP-III values were found to be elevated in patients with 
rheumatic diseases who had clear evidence of vasculitis. Particularly in the patients 
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Fig. 4. The upper panel shows that in systemic lupus erythematosus patients, an elevated pCTAP-III 
usually occurs ‘in the setting of a reduced CH,,, while the lower panel suggests that an elevated 
pCTAP-III was usually found with an abnormal DNA-binding value. 
with RA and SLE, elevated pCTAP-III values occurred very frequently in associa- 
tion with the laboratory and clinical parameters of “clinical disease activity”. The 
limited study population renders elaborate statistical analysis no more helpful than 
inspection of the data. It is important to note that the data basically reflect platelet 
activation and secretion of specific protein mediators, presumably within a few 
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Fig. 5. Increased DNA binding and reduced CH,, values usually occur together. 
hours of sampling in view of data indicating that the half-life of this molecular 
species is of the order of 100 min [23]. 
It is also important to recall that secretion may not necessarily require aggrega- 
tion and release such as might occur at a site of endothelial injury. For instance, 
IgG, IgM and fibrinogen are known to enhance platelet aggregation in vitro [24]; 
interaction of RA platelets with insoluble IgG-rheumatoid factor complexes results 
TABLE I 
PLASMA CTAP-III LEVELS IN DIFFERENT RHEUMATIC DISEASES 
Rheumatic disease pCTAP-III 
(n&ml) 
Disease activity 
Wegener’s (I) 28 
Wegener’s (2) 135 
Scleroderma (1) 120 
Scleroderma (2) 31 
Scleroderma (3) 20 
Polymyalgia rheumatica 34 


















































































































































































































































































































































































































































































































































in release of platelet products such as serotonin [25]. Elevated pCTAP-III levels in 
SLE might also be explained by immune complex induced endothelial cell injury 
with subsequent platelet aggregation and release of platelet growth factors. In 
addition to thrombocytosis, rheumatoid patients may exhibit an increased rate of 
platelet turnover and decreased platelet half-life [9]. There is evidence that thrombo- 
cytosis often correlates with RA disease activity and extra-articular manifestations 
[lo], and recent studies show that RA platelets contain decreased acid phosphatase, 
spine-soluble protein and CTAP-III [26]. In the present study, no relations~p 
between pCTAP-III levels and circulating platelet count was noted for any of the 
disease entities studied. 
It is important to not over-interpret the current evidence, and in this vein, it 
should be noted that the radioimmunoassays available do not distinguish between 
biologically active CTAP-III and biologically inactive P-TG. The assay does in fact, 
primarily reflect recent platelet secretion of the antigenic material. In this context, it 
is also important to note that the levels of circulating antigen measured in disease 
states, even though elevated, would not be expected to exert a significant effect on 
sensitive peripheral connective tissue cells. The concentrations measured, even if 
entirely composed of biologically active CTAP-III are believed, on the basis of in 
vitro experiments, to be too low to exert biological effects. It seems likely that these 
materials are primarily active in the micro-environment at the site of platelet 
secretion. 
It is attractive to postulate a hypothetical role for this platelet-derived growth 
factor based on its known capacity to stimulate connective tissue cell DNA synthesis 
and formation of connective tissue matrix components. One might visualize CTAP-III 
as an important signal mechanism in the inflammatory process. The platelet growth 
factor (CTAP-III) might have a role in the pathogenesis of inflammation, chronic 
vascular disease and the growth and repair of connective tissue by virtue of its 
ability to “activate” connective tissue cells at the site of injury with -consequent 
increase in connective tissue cell replication and formation of extracellular matrix 
materials. Further studies are needed to determine whether the findings in patients 
are of a primary pathogenetic si~ificance or are a secondary phenomenon. 
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